ACE Report Cover
Use of local infusion analgesia for expedited patient recovery following THA
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
ARTHROPLASTY
Use of local infusion analgesia for expedited patient recovery following THA .
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(2):4 Acta Orthopaedica 2011; 82 (2): 315–320.

60 patients undergoing non-cemented total hip arthroplasty and receiving standard pain treatment in the form of local infiltration analgesia (LIA) were randomized to receive either placebo or a postoperative solution of local infusion analgesia (LINFA). Postoperative assessments of pain, opioid consumption, and length of hospital stay indicated similar results for both groups.


Publication Funding Details +
Funding:
Not Reported
Conflicts:
None disclosed

Risk of Bias

9/10

Reporting Criteria

20/20

Fragility Index

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Yes = 1

Uncertain = 0.5

Not Relevant = 0

No = 0

The Reporting Criteria Assessment evaluates the transparency with which authors report the methodological and trial characteristics of the trial within the publication. The assessment is divided into five categories which are presented below.

4/4

Randomization

4/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

The Fragility Index is a tool that aids in the interpretation of significant findings, providing a measure of strength for a result. The Fragility Index represents the number of consecutive events that need to be added to a dichotomous outcome to make the finding no longer significant. A small number represents a weaker finding and a large number represents a stronger finding.

Why was this study needed now?

The use of LINFA postoperatively to supplement LIA, following total hip arthroplasty, has increased significantly throughout clinical practices, as a means to expedite patient recovery. There currently exists a lack of RCTs regarding the efficacy of LINFA and supporting its use postoperatively.

What was the principal research question?

Does a postoporative LINFA regimen lead to reduced nausea and expedited patient recovery, as compared to a placebo control in patients undergoing total hip arthroplasty for primary osteoarthritis?

Study Characteristics +
Population:
60 patients undergoing total hip arthroplasty for primary hip osteoarthritis
Intervention:
LINFA-Following surgery: patients were administered 200 mg Ropivacaine, 30 mg Ketorolac, 1 mg Adrenaline through a catheter into the intra-articular capsule. Doses were administered at the 10 and 22 h marks, post-surgery (n=30).
Comparison:
Control-Following surgery: patients were administered a saline solution through a catheter into the intra-articular capsule. Saline doses were administered at the 10 and 22 h marks, post-surgery (n=30).
Outcomes:
WOMAC scale for pain, opioid consumption, postoperative nausea and vomiting (PONV), tiredness, LOS (length of stay).
Methods:
RCT: Single-Center, including 60 patients
Time:
7 days postoperative
What were the important findings?
  • There was a reduction in nausea and vomiting in the LINFA group (p=.02) in the short term (days 1 and 2)
  • There was not a significant difference between the two groups in terms of the WOMAC pain scale, opioid consumption, and tiredness
  • There was not a statistically significant difference detected in terms of length of stay; however, the results were trending towards a reduction in stay in the LINFA group (p=.09)
What should I remember most?

There was no significant difference established with respect to pain management, length of stay or tiredness. There was some indication that LINFA was associated with reduced nausea and vomiting during the early post-operative stage.

How will this affect the care of my patients?

The authors contend that although LIA with postoperative LINFA has become common clinical practice, there exists no documented benefit of LINFA with regards to patient recovery, pain, or tiredness. However, small sample size of this study should be taken into account.

DISCLAIMER

This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.

0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Your account will be affiliated with
and includes free access to OrthoEvidence


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

How to cite this ACE Report

OrthoEvidence. Use of local infusion analgesia for expedited patient recovery following THA. OE Journal. 2013;1(2):4. Available from: https://myorthoevidence.com/AceReport/Show/use-of-local-infusion-analgesia-for-expedited-patient-recovery-following-tha

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report